Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

NovaBay Pharmaceuticals (NBY) EBIT Margin (2016 - 2025)

Historic EBIT Margin for NovaBay Pharmaceuticals (NBY) over the last 17 years, with Q3 2025 value amounting to 241.07%.

  • NovaBay Pharmaceuticals' EBIT Margin changed N/A to 241.07% in Q3 2025 from the same period last year, while for Sep 2025 it was 41.16%, marking a year-over-year increase of 572400.0%. This contributed to the annual value of 59.7% for FY2024, which is 204600.0% down from last year.
  • NovaBay Pharmaceuticals' EBIT Margin amounted to 241.07% in Q3 2025.
  • In the past 5 years, NovaBay Pharmaceuticals' EBIT Margin ranged from a high of 2.33% in Q4 2024 and a low of 258.74% during Q4 2022
  • Its 5-year average for EBIT Margin is 86.73%, with a median of 78.42% in 2022.
  • Per our database at Business Quant, NovaBay Pharmaceuticals' EBIT Margin tumbled by -1580800bps in 2022 and then skyrocketed by 2107700bps in 2023.
  • NovaBay Pharmaceuticals' EBIT Margin (Quarter) stood at 100.66% in 2021, then tumbled by -157bps to 258.74% in 2022, then soared by 81bps to 47.98% in 2023, then soared by 95bps to 2.33% in 2024, then crashed by -10242bps to 241.07% in 2025.
  • Its last three reported values are 241.07% in Q3 2025, 2.33% for Q4 2024, and 43.88% during Q2 2024.